High Prevalence of *Helicobacter pylori* Infection, Atrophic Gastritis and Hypochlorhydria in HIV-Positive Cameroonians tested by Serological Stomach-Specific Biomarkers (GastroPanel®)

## Abstract

The human immunodeficiency virus (HIV) and Helicobacter pylori (H. pylori) are associated with significant chronic inflammation of the gastric mucosa. Gastric inflammation is a precursor to many gastrointestinal disorders including, peptic ulcer disease, atrophic gastritis (AG) and gastric cancer (GC). AG is usually accompanied by low hydrochloric acid (hypochlorhydria), low pepsinogens (PG) and high gastrin (G) levels and is the most significant risk condition for GC. Acid-free stomach is a risk factor for impaired drug absorption including anti-retroviral therapy and antibiotics. The role of *H. pylori* infection in HIV-infected subjects has been conflicting. We assessed the prevalence of *H. pylori* infection, AG and acid-free stomach (hypochlorhydria) amongst HIV/AIDS subjects in Yaounde Cameroon. A total of 84 HIV/AIDS subjects were recruited in during January-May 2018. Clinical and socio-demographic data of the subjects were recorded. An aliquot of 5 ml of blood was aseptically collected for analysis by GastroPanel® biomarker test for PGI, PGII, G-17 and H.pylori IgG antibodies. GastroPanel results wer interpreted using the software application GastroSoft®. Statistical analyses were run by Epiinfo7.0. Ethical clearance was obtained from the National Ethics Committee. A total of 84 subjects were recruited, aged between 17-63 years(mean  $37.6 \pm 8.9$  years). *H. pyloriseropositivity* (IgG  $\geq$ 30 EIU) was detected in 68(81.0%) of the subjects. *H. pylori* seropositivity was closely associated with low CD4 counts (p=0.01). Altogether, 26(31.0%) of the subjects presented with AG of the corpus while, hypochlorhydria was detected in 32(38.1%) of the patients. AG and hypochlorhydria were associated with low CD4 counts<200µl/l (p=0.01) and (p=0.005), respectively. Conclusion: H. pylori infection, AG and acid-free stomach were common among HIV/AIDS patients, associated with an increased risk for GC and impaired absorption of micronutrients and some medicines.

# Key words: Helicobacter pylori, atrophic gastritis, hypochlorhydria, HIV, Serological biomarkers, GastroPanel test; GastroSoft application, pepsinogens, Gastrin-17

"The study (original research), entitled "High Prevalence of *Helicobacter pylori* Infection, Atrophic Gastritis and Hypochlorhydria in HIV-Positive Cameroonians tested by Serological Stomach-Specific Biomarkers (GastroPanel®)" was conducted by us as an original work and has not been published anywhere else".

# Introduction

Human immunodeficiency virus(HIV) infection is commonin Cameroon. It is estimated that over 600.000 persons live with HIV, with a population prevalence of 4.8%. Dyspepsia-like symptoms are very frequent amongst HIV/AIDS subjects during the course of their disease [1].*Helicobacter pylori* (*H. pylori*) remains one of the most common infectious agents worldwide, with an estimated prevalence of >80% in certain underprivileged populations in Africa [2].*H. pylori*-associated chronic active gastritis usually progresses into atrophic gastritis (AG) and acid-free or hypochlorhydric stomach, both being well established risk factors of gastric cancer (GC) [3].

HIV and *H. pylori* are associated with marked chronic inflammation of the gastric mucosa. Once progressed to AG, this chronic inflammation leads to hypochlorhydria and finally acid-free stomach, characterized by low serum levels of pepsinogen I and II (PG I and PGII), and refractory elevation of serum gastrinlevels. Apart from GC, acid-free stomach is a risk factor for enteric infections and impaired absorption of drugs, including those used in anti-retroviral therapy and antibiotics [4].

Gastrins are peptide hormones that stimulate gastric acid (HCl) output by gastric parietal cells, the biologically most active being gastrin-17 (G-17). G-17 release by G-cells in the gastric antrum is stimulated by the presence of food in the stomach. G-17 release is also regulated by feedback inhibition via somatostatin from the adjacent D-cells in the presence of a low gastric pH [5]. High fasting blood levels of G-17 are typical to patients with chronic gastritis (caused by *H. Pylori* infection or autoimmune disease) [5, 6]. Chronic AG leads to the loss of parietal cells in the corpus, with hypochlorhydria, acid-free stomach and high G-17 levels as end results.

*H. pylori* infection itself can also cause mild increase of G-17, triggered by the inflammatory process in the mucosa [4]. Several studies have reported higher serum G-17 concentrations among HIV-positive patients [7,8] while one study failed to demonstrate any effect of THE HIV-status on serum gastrin levels [9]. The role of *H. pylori* infection in HIV-infected subjects has been conflicting. Several studies have reported low prevalence of *H. pylori* 

amongst HIV- positive subjects [1, 2, 10-13]. In contrast, higher *H. pylori* prevalence has been reported in some other studies [4, 14, 15].

Endoscopy with targeted mucosal biopsies is effective in screening of the upper GI-tract malignancies. However, this invasive method is uncomfortable, distressing and quite costly, emphasizing the need for rapid, reliable and inexpensive non-invasive tests [16,17]. Recently, a plasma biomarker panel with combination of PGI,–PGII, G-17 and *H. pylori* IgG antibodies using an ELISA technique was developed, known as GastroPanel® test (BiohitOyj, Helsinki, Finland). GastroPanel is intended for the first-line diagnosis of dyspeptic patients and for screening of the risk groups of GC, i.e. to detect the subjects with AG[18-21]. In the present study, GastroPanel test was used to assess the prevalence of *H. pylori* infection, AG and hypochlorhydriain HIV/AIDS patients (in Yaounde, Cameroon), with biomarker levels related to the CD4 counts.

#### Methods

The material of this study consisted of 84 HIV/AIDS patients recruited at the Jammot Hospital of Yaounde Cameroon during the five-month period January-May 2018. Authorizations were obtained at the Jammot Hospital of Yaounde, and ethical approval was granted by the National Ethics committee (No 0174/CRERSHC of February 05<sup>th</sup> 2018). All patients signed an informed consent.

Clinical and socio-demographic information of patients were recorded. As an essential anamnestic data for GastroPanel test, the participants were enquired for their intake of non-

steroidal anti-inflammatory drugs, treatment of antibiotics, use of proton pump inhibitors (PPI), H2-receptor antagonists and anti-retroviral therapy.

For the GastroPanel test, an aliquot of 5 ml of blood was aseptically collected in EDTA anticoagulated tubes, which was kept undisturbed for 1 hour for plasma formation. The tubes were subsequently centrifuged at 1500rpm for 5 minutes. The plasma obtained was transferred into sterile cryotubes and stored at -20°C, for GastroPanel analysis, following the manufacturer's instructions. The biomarker profiles for PGI, PGII, G-17, and *H.pylori* IgGwere interpreted using theGastroSoft software application [22]. All patients with *H. pylori* IgG $\geq$  30 EIU were considered positive for *H. pylori* infection. All patients with PGI < 30 µg/l and/or PGI/PGII < 3.0 and those with G-17 < 1pmol/l were considered positive for AGof the corpus and AG of the antrum, respectively. Subjects with G-17 >7pmol/l were considered as having hypochlorhydria.

All statistical analyses were conducted by Epi Info software 7.0 (the Centers for Disease Control and Prevention, CDC, Atlanta, GA, USA). Conventional Chi square test was applied to test the difference between two proportions; student (t) test was applied to test the difference of more than two means. All analyses were two-sided, and P value <0.05 was regarded as statistically significant.

# Results

Altogether, 84 subjects with HIV/AIDS were recruited, aging between 17-63 years, with a mean age of  $37.6 \pm 8.9$  (SD) years. Of the 84 patients, 54(64.3%) were females (aged 21-63, mean 36.7  $\pm$  8.6 years) and 30(35.7%) were males aged 17-60, mean 39.1  $\pm$  9.6 years. Elevated levels of Anti H. pyloriantibodies (IgG  $\ge$  30 EIU) were detected in 68/84 (81.0%) of the patients. In all age groups, higher sero-prevalence of anti H. pylori antibodies were noticed in the HIV subjects(Table 1), with H. pylori seroprevalence of 83.3%, 77.3% and 100.0% in HIV+ age groups 17-35, 36-54 and 55-73 years, respectively (p=0.48). H. pylori IgG seropositivity was not associated with the sex; females (85.2%) and males (73.3%), (p=0.10).*H. pyloriseropositivity was significantly associated with low CD4 counts (* p=0.01). When AG was classified into various grades, 52(63.9.0%) presented with non-atrophic (superficial Hp-gastritis) while 26(31.0%) were diagnosed with AGof the corpus. In addition, 32(38.1%) of the subjects presented with hypochlorhydria (Table2). AG and hypochlorhydria were associated with low CD4 counts<200µl/l (p=0.01) and (p=0.005), respectively. High G-17 levels (G-17 >7pmol/l) were more frequently associated with AG of the corpus than with superficial gastritis ( $16.44\pm18.40$  vs.  $10.03\pm9.2$  pmol/l; p=0.03). The same is true with G-17 levels and hypochlorhydria as compared with normal acid levels (15.26±16.73 vs. 10.02± 9.73pmol/l).

# Discussion

The role of *H. pylori* infection among HIV-infected subjects remains controversal [1, 15]. In the present study, seropositivity of *H. Pylori* was 68/84 (81,0%), which is very similar as previously reported among dyspeptic subjects in Cameroon [23] (81,40%), [24] (79,80%), [18] (78,7%) and in some other countries e.g. 76,5% in Kazakhstan [16]. This *H. pylori* seroprevalence is also similar with that (80.5%) reported previously in diabetic subjects in our country [25]. This high prevalence of *H. pylori* among HIV/AIDS subjects is in alignment with the figures reported from ther countries including:Malawi using histology(71,6%)[4], as well as Ethopia using IgG serology(85,6%)[15].

However, the seroprevalence of 81% in the present study is substantially higher than detected among HIV/AIDS patients in some other countries using different detection techniques, including histology and a rapidurease test (RUT) in Cameroon(59%) [26], and 50% [1], respectively. The figures were even lower (37.2%) in Brasil [11], those obtained by histology(22,1%) in China[10]; stoolantigen test (SAT) in Ouganda(22,5%) [13], or those (46.8%) in Nigeria[12]. Undoubtedly, these divergent figures in the prevalence of *H. pylori* reported among HIV-subjects are due to different diagnostic techniques. Histology, UBT and SAT used in most studies are associated with false negative results especially in certain medical conditions such as peptic ulcer, AG, MALT lymphoma and partial gastrectomy[20,21,27-30]. In addition, decreased bacterial load may result from prolonged use of certain medications with antimicrobial properties including PPI, NSAIDS and antibiotics, and lead to false negative results in many studies[20]. On the other hand, UBT may also give false positive results in cases where acid-free stomach is colonized by ureasepositive bacterial species other than H. pylori [31]. These false negative and false positive results in *H. pylori* diagnosis can now be avoided with the simple GastroPanel test[19,20,31]. Although the majority of *H. pylori* infections and AG have been associated with age and male gender [5,32,33], we did not find any association of *H. pylori* prevalence with age(p=0,48)or sex (p=0,10). However, we observed an elevated *H. pylori* prevalence among subjects with low CD4 (p=0.01) (Table 1). This observation was not confirmed in some studies [1,2,26]. Given that *H. pylori* infection is usually contracted at childhood, it could

have facilitated the destruction of CD4 cells by HIV-virus. According to Magen *et al.*[14], *H. pylori* stimulates the activation of CD4+, CCR5+and CCR4+which are receptors and coreceptors for HIV.

In the present analysis of GastroPanel biomarker profile, AG of the corpus occured in 26 (31,0%) of the subjects(PGI <30 $\mu$ g/l) and lowacid output (hypoclorhydria) in 32 (38,1%) (G-17>7pmol/l) of the study subjects. This high prevalence of AG of the corpus and hypochlorhydria among HIV subjects substantiate the figures reported in previous studies [1,11,26]. Such a high prevalence of AG is, however, in contrast to what has been reported among dyspeptic subjects[18,19,23,24,34,35,36].This high prevalence (>30%) of corpus AG implicates that HIV/AIDS patients are at substantially higher risk of GC as compared to the general population.

In addition, we observed a close association between low CD4 counts and 1) AG (p=0,005) as well as 2) hypochlorhydria(p=0,01). Similar observations have been reported before [4,26]. AG and hypochlorhydria (low acid output) observed in HIV/AIDS subjects may suggest the risk of enteric infections, poor absorption of ARV, Vitamin-B12, and certain divalent micronutrients including iron, calcium, magnesium and zinc [3-6,37], with increased risk of clinically important sequels, like cognitive disorders, neurodegenerative and vascular disorders, encephalopathies, anemias and osteoporosis.

### Conclusions

We report high prevalence of *H. pylori* infection amongst HIV/AIDS subjects similar to those in dyspeptic and diabetic subjects. We also report high prevalence of atrophic corpus gastritis and hypochlorhydria in these patients. *H. pylori* infection and AG represent the most important risk factors for GC and oesophageal cancer. Accordingly, HIV/AIDS subjects may be at increased risk of GC and impaired absorption of micronutrients and some medicines, thus requiring continuous monitoring and follow-up. This can be neatly accomplished by non-invasive GastroPanel test, closely reflecting both the structure and function of the stomach, in addition of being the most comprehensive test for *H. pylori* infections, devoid of the limitations of UBT and SAT tests [31].

#### DECLARATION

**Availability of data and materials** All data used during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate.** Ethical clairance was obtained from Center Regional Committee for Research on Human Health (CRERSH) No 0174/CRERSHC/2018 of 05 February 2018. An authorization was obtained the authorities of the Jamot Hospital of Yaounde. All patients signed an informed consent form.

### References

- Andoulo FA, Kowo M, Ngatcha G, Ndam AN, Awouoyiegnigni B, Sida MB, Tzeuton C,NdjitoyapNdam EC. Prévalence de l'infection à Helicobacter pylori au travers de l'endoscopie digestive haute chez les patients VIH/sida avec des symptômes gastrointestinaux dans les hôpitaux universitaires au Cameroun, *Med Sante Trop.* 2016;26: 278-82.
- Nevin T. Daniel, Morgan J. Christopher, Graham Y. David and GentaM.Robert. Helicobacter pylori Gastritis in HIV-Infected Patients: A Review.*Helicobacter* 2014 DOI: 10.1111/hel.1213
- Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, Van Oijen M, Perez Perez G, Rugge M. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. *Scand J Gastroenterol*.2012 Feb 1;47(2):136-47.
- Geraghty J, Thumbs A, Kankwatira A, Andrews T, Moore A, Malamba R, et al. *Helicobacter pylori*, HIV and Gastric Hypochlorhydria in the Malawian Population. *PLoS ONE*. 2015 10(8): e0132043. doi:10.1371/journal.pone.0132043
- 5. Di Mario F, Franzè A, Cavallaro LG. Non-invasive approach to diagnosis of upper gastrointestinal diseases.1st ed. AREA QUALITÀ s.r.l; 2008.5-64.
- Ebule IA. GastroPanel For The Diagnosis Of Gastritis: A Tool For Health Emmergence. 1<sup>st</sup> ed. Yaounde: NYA PUBLISHERS; 2016; 1:1-82.
- Herzlich BC, Schiano TD, Moussa Z, Zimbalist E, Panagopoulos G, Ast A, *et al.* Decreased intrinsic factor secretion in AIDS: relation to parietal cell acid secretory capacity and vitamin B12 malabsorption.*Am J Gastroenterol.* 1992 Dec; 87(12):1781– 8. PMID:1449141

- Fabris P, Pilotto A, Bozzola L, Tositti G, Soffiati G, Manfrin V, *et al.* Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4+ cell count and Helicobacter pylori infection. *Aliment PharmacolTher. Blackwell Science Ltd*; 2002 Apr 1; 16(4):807–11.
- Shaffer RT, LaHatte LJ, Kelly JW, Kadakia S, Carrougher JG, Keate RF, et al. Gastric acid secretion in HIV-1 infection. *Am J Gastroenterol*. 1992 Dec; 87(12):1777–80. PMID:1449140.
- Lu FJ, Luo XL, Meng X, Jin R, Ding HG, Zhang ST. A low prevalence of *H pylori* and endoscopic findings in HIV-positive Chinese patients with gastrointestinal symptoms. *World J Gastroentero.l* 2007; 13(41): 5492-5496
- 11. Fialho ABC, Braga-Neto MB, Guerra Eder JC, Fialho AMN, FernandesKC, Sun JLM, Takeda CFV, Silva Cícero IS, QueirozDulciene MM, Braga Lucia LBC: Low prevalence of H. pylori Infection in HIV-Positive Patients in the Northeast of Brazil. BMC Gastroenterol. 2011;11(13). Available from: www.biomedcentral.com/1471-230X/11/13
- 12. Anejo-Okopi AJ, Audu O, Adaiche AR,Okojokwu OJ, Ali M, Adekwu A,Lar P, Smith SI. Prevalence of *Helicobacter pylori* Infection among HIV-1 Infected patients using Stool Antigen Tests in Jos, North-Central, Nigeria. *Govaresh* 2016;21:55-63.
- Hestvik E, Tylleskar T, Ndeezi G, Grahnquist L, Olafsdottir E, Tumwine KJ, Kaddu-Mulindwa HD. Prevalence of *Helicobacter pylori* in HIV-infected, HAART-naïve Ugandan children: a hospital-based survey.*J Int AIDS Soc*.2011;14(34):1-9.Availablefrom: www.jiasociety.org/content/14/1/34
- 14. Magen E, Elbirt D, Agmon-Levin N, Mishal J, Sthoeger Z. Eradication of *Helicobacter pylori* can facilitate immune reconstitution in HIV-1-infected immunological non-responders. *Int J Infect Dis*. 2010;14:e322–e327
- 15. Moges F, Kassu A, Mengistu G, Adugna S, Andualem B, Nishikawa T, Ota F. Seroprevalence of *Helicobacter pylori* in dyspeptic patients and its relationship with HIV infection, ABO blood groups and life style in a university hospital, Northwest Ethiopia. *World J Gastroenterol.* 2006; 12(12): 1957-1961. Available from:www.wjgnet.com/1007-9327/12/1957.asp
- Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K. Prevalence of *H. pylori* infection and atrophic gastritis among

symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. *AnticancerRes.* 2013;33(10):4595-602.

- Bornschein J, Selgrad M, Wex T, Kuester D and Malfertheiner P. Serological assessment of gastric mucosal atrophy in gastric cancer. *BMC Gastroenterol.* 2012; 12:10
- Ebule IA, Djune FAK, Njeambosay BA, DohG N, Befolo MHDM, Nkayo M, et al. Atrophic Gastritis and Gastric Cancer Risk amongst Diabetes Mellitus Type 2 Subjects and Controls in Yaounde Cameroon. Using a Panel of Serum Biomarkers (PGI,G-17).J Clin GastroenterolTreat.2017;3:052. doi.org/10.23937/2469-584X/1510052
- 19. Kurilovich S, Belkovets A, Reshetnikov O, Openko T, Malyutina S, Ragino Y, Scherbakova L, Leja M, Paloheimo L, Syrjänen K, Voevoda M. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. *Anticancer res.* 2016 Jan 1;36(1):247-53.
- 20. Syrjänen K. False Positive and False Negative Results in Diagnosis of Helicobacter PyloriInfection Can be avoided by A Panel of Serum Biomarkers (GastroPanel®). *M J Gast.* 2017;1(1):007.
- 21. Syrjänen K. Serological Biomarker Panel (GastroPanel®): A Test for Non-Invasive Diagnosis of Dyspeptic Symptoms and for Comprehensive Detection of Helicobacter pylori Infection.*Biomark J.* 2017;3:1(2).DOI:10.21767/2472-1646.100024.
- 22. <u>www.gastropanel.net</u>/www.biohithealthcare.com
- 23. Noah Noah D, Marie Claire OA, Servais Albert Fiacre EB, Guy PN, Ebule IA, Lea P, Oudou N. Assessing GastroPanel serum markers as a non-invasivemethod for the diagnosis of atrophic gastritis and *Helicobacter pylori* infection. *O J Gast.* 2012 Aug 30;2:113-118
- 24. Ebule IA, Longdoh AN, Paloheimo IL. *Helicobacter pylori* infection and atrophic gastritis. *Afr Health Sc.* 2013;13(1)112-117.
- 25. Ebule IA, Djune FAK, Njeambosay BA, Doh GN, Metaghue G, Majuikouo L, et al. Association of Helicobacter Pylori Infection and Diabetes Mellitus Type 2 Subjects in Yaounde Cameroon. Using a Panel of Serum Biomarkers (PGII, HpIgG): A Case Control Study. J ClinGastroenterol Treat. 2017;3:053.doi.org/10.23937/2469-584X/1510053

- 26. Firmin A, Mathurin K, Antonin WNN, Benjamin A, Oudou N, Magloire BS, Christian T, Elie Claude NN. The Prevalence of *Helicobacter Pylori* Infection and Peptic Ulcer Disease in HIV-Positive Patients with Gastrointestinal Symptoms isnot Related to Absolute CD4 Counts: A Case-Control Study. *Health Sci. Dis.* 2016;17(1):1-5. Available from: www.hsd-fmsb.org
- 27. Kokkola A, Rautelin H, Puolakkainen P, Sipponen P. Diagnosis of *Helicobacter pylori* infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. *Scand J Gastroenterol*. 2000;35(2):138-141
- 28. Barkun AN, Bardou M and Kuipers EJ. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101-113
- 29. Malfertheiner P, Megraud F, O'morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM. Management of *Helicobacter pylori* infection—the Maastricht IV/Florence consensus report.*Gut*.2012;61(5):646-64.
- 30. Zagari RM, Romano M, Ojetti V, Stockbrugger R. Guidelines for the management of *Helicobacter pylori* infection in Italy: The III Working Group Consensus Report. *Dig Liver Dis*. 2015;47(11):903-912.
- 31. Syrjänen K. Caveats in Diagnosis of Helicobacter Pylori Infection can be Avoided by a Panel of Serum Biomarkers (GastroPanel®). J Carcinog Mutagen 2016;7:e123. doi:10.4172/2157-2518.1000e123
- 32. International Agency for Research on Cancer, World Health Organization Schistosomes, Liver flukes and *Helicobacter pylori*. IARC working group on the evaluation of carcinogenic risks to human. *MonogrEvalCarcinogRisks Hum* 1994; 61:218-20.
- 33. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetesmellitus patients. *Dig Dis Sci*1996;41:458-461.
- 34. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study.*Scand J Gastroenterol* 2008;43:1448-1455.
- 35. Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M, Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. *Scand J Gastroenterol* 2010;45: 1036-1041

- 36. Syrjänen K, Eronen K. Serological Testing in Management of Dyspeptic Patients and in Screening of Gastric Cancer Risks. *J GastrointestDisord Liver Func.* 2016;2(3): 1-5.
- Sipponen P, Maaroos HI. Chronic gastritis. ScandJ Gastroenterol. 2015 Jun 3;50(6):657-67.

Table1: Socidemographic data of the HIV- subjects related to H. pylori serostatus

H	<i>H.pylori</i> Positive ( <b>IgG≥30EIU</b> ) 68(81.0%)	H.pylori	P-value
( 6		Negative(IgG<30EIU)	
		16(19.0%)	

Pepsinogen(PGI/µg/l)	94.63±87.73	$126,8 \pm 126,2$	0.23
Pepsinogen(PGII /µg/l)	$50.53\pm38.06$	$30,18 \pm 24,63$	0.045
PGI/PGII ratio	$4.49 \pm 11.07$	3.68 ± 1.33	0.80
Gastrin-17(G17/pmol /l)	$13.2\pm 14.23$	$7.76\pm2.79$	0.15
H. pylori(IgG / EIU)	260.27±203.27	$21.00 \pm 4.78$	0.00001
CD4			
0-199	54(84.4%)	10(15.6%)	
200-499	10(83.3%)	2(16.7%)	0.01
500-1000	2(33.3%)	4(66.7%)	
Sex			
Males	22(73.3%)	8(26.7%)	0.10
Females	46(85.2%)	8(14.8%)	
Age(yrs)	. ,		
17-35	30(83.3%)	6(16.7%)	
36-54	34(77.3%)	10(22.7%)	0.48
55-73	4(100%)	0(0.0%)	
ATB			
Yes	26(76.5%)	8(23.5%)	
No	42(84.0%)	8(16.0%)	0.20
	× ,	<b>``</b>	
NSAIDS			
Yes	4(50%)	4(50%)	0.04
No	64 (84.2%)	12 (15.8%)	
PPI			
Yes	22(100%)	0(0%)	0.004
No	46(74.2%)	16(25.8%)	
HAART			
Yes	18(69.2%)	8(30.8%)	0.07
No	50(86.2%)	8(13.8%)	

ATB: antibiotics, NSAIDS: non steroidal anti inflammatory drugs, PPI: proton pump inhibitors, HAART: highly active antiretroviral therapy

Table 2: Atrophic gastritis	(AG) and hypochlorhydi	ria in HIV-positive subjects
		I J

	/ /1	2	1	J	
AtrophicGastritis	Non atrophic	p-	Hypochlorhydria	Hypochlorhydria	p-
<i>C</i> :( <b>PGI &lt;30µg/l</b> )	Gastritis	value	Yes(G17>pmol /l)	No	value
26(31.0%)	S: 58(69.0%)		32(38.1%)	52(61.9%)	

Pepsinogen PGI (µg/l)	$28.37 \pm 8.93$	133.31 ± 99.84	0.0000 1	56.32 ± 86,12	128.2 ± 92.4	0.001
Pepsinogen PGII (µg/l)	$42.29 \pm 41.58$	48,61± 34,43	0,47	42,14±39,92	49.42±34.59	0.38
PGI/PGI ratio	$1.19 \pm 1.02$	5.62±11.75	0.06	$1.74 \pm 1.49$	5.79 ± 12.41	0.07
Gastrin-17 G17(pmol /l)	16.44±18.40	10.03±9.2	0.03	15.26±16.73	$10.02 \pm 9.73$	0.07
H. pylori IgG(EIU)	204.4± 254.9	219.3± 181.7	0.76	$170.8 \pm 239.7$	241.7± 178.7	0.13
CD4						
0-199 200-499 500-1000	26(40.6%) 0(0%) 0(0%)	38(59.4%) 12(100%) 6(100%)	0.005	28(43.8%) 0.00 4(66.7%)	36(56.3%) 12(100) 2(33. 3%)	0.006
Sex				12(40.0%)		
Males Females	10(33.3%) 16(29.6%)	20(66.7%) 38(70.4%)	0.36	20(37.0%)	18(60.0%) 34(63.0%)	0.40
Age(yrs) 17-35 36-54 55-73	14(38.29%) 12(27.3%) 0(0%)	22(61.7 1%) 32(72.7%) 4(100%)	0.21	16(44. 4%) 16(36. 4%) 0(0%)	20(55.6%) 28(63.6%) 4(100%)	0.21